KR100875611B1 - ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품 - Google Patents

ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품 Download PDF

Info

Publication number
KR100875611B1
KR100875611B1 KR1020037015721A KR20037015721A KR100875611B1 KR 100875611 B1 KR100875611 B1 KR 100875611B1 KR 1020037015721 A KR1020037015721 A KR 1020037015721A KR 20037015721 A KR20037015721 A KR 20037015721A KR 100875611 B1 KR100875611 B1 KR 100875611B1
Authority
KR
South Korea
Prior art keywords
delete delete
pat
cci
rapamycin
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037015721A
Other languages
English (en)
Korean (ko)
Other versions
KR20040025923A (ko
Inventor
듀카트게리
기봉스제임스조셉쥬니어
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20040025923A publication Critical patent/KR20040025923A/ko
Application granted granted Critical
Publication of KR100875611B1 publication Critical patent/KR100875611B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020037015721A 2001-06-01 2002-05-29 ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품 Expired - Fee Related KR100875611B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01
US60/295,236 2001-06-01
US60/295,190 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (2)

Publication Number Publication Date
KR20040025923A KR20040025923A (ko) 2004-03-26
KR100875611B1 true KR100875611B1 (ko) 2008-12-24

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037015721A Expired - Fee Related KR100875611B1 (ko) 2001-06-01 2002-05-29 ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품

Country Status (17)

Country Link
EP (1) EP1392286A2 (enExample)
JP (1) JP2004532883A (enExample)
KR (1) KR100875611B1 (enExample)
CN (1) CN100496485C (enExample)
AU (2) AU2002259309B2 (enExample)
BR (1) BR0210101A (enExample)
CA (1) CA2447732A1 (enExample)
CO (1) CO5540294A2 (enExample)
EA (1) EA007530B1 (enExample)
HU (1) HUP0400006A2 (enExample)
IL (1) IL158800A0 (enExample)
MX (1) MXPA03010907A (enExample)
NO (1) NO20035317L (enExample)
NZ (1) NZ529877A (enExample)
PL (1) PL367267A1 (enExample)
SG (1) SG153647A1 (enExample)
WO (1) WO2002098416A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3351246T (lt) * 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
AU2006311877A1 (en) * 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
US9006224B2 (en) * 2005-11-21 2015-04-14 Novartis Ag Neuroendocrine tumor treatment
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
EP2591775A1 (en) 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
LT2481409T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SI2310011T1 (sl) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
BRPI0916694B1 (pt) 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT3351246T (lt) * 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui

Also Published As

Publication number Publication date
JP2004532883A (ja) 2004-10-28
EP1392286A2 (en) 2004-03-03
IL158800A0 (en) 2004-05-12
WO2002098416A2 (en) 2002-12-12
KR20040025923A (ko) 2004-03-26
HUP0400006A2 (hu) 2004-04-28
EA200301319A1 (ru) 2004-04-29
CN100496485C (zh) 2009-06-10
SG153647A1 (en) 2009-07-29
MXPA03010907A (es) 2004-02-17
BR0210101A (pt) 2004-06-08
CA2447732A1 (en) 2002-12-12
CO5540294A2 (es) 2005-07-29
NO20035317D0 (no) 2003-11-28
NZ529877A (en) 2006-08-31
WO2002098416A3 (en) 2003-03-13
PL367267A1 (en) 2005-02-21
EA007530B1 (ru) 2006-10-27
NO20035317L (no) 2003-12-22
AU2008202690A1 (en) 2008-07-10
CN1646120A (zh) 2005-07-27
AU2002259309B2 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
KR100862178B1 (ko) 라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물
US20030008923A1 (en) Antineoplastic combinations
AU2008202690A1 (en) Antineoplastic combination
US7189735B2 (en) Use of CCI-779 as an antineoplastic agent
RU2451524C2 (ru) Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
US20060035904A1 (en) Antineoplastic combinations
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
WO2010049481A1 (en) Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
AU2002259309A1 (en) Antineoplastic combinations
ZA200309816B (en) Antineoplastic combinations
US20050187184A1 (en) Antineoplastic combinations
AU2002227313B2 (en) Use of CCI-779 as an antineoplastic agent
HK1060062B (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
AU2002257123A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
AU2002227313A1 (en) Use of CCI-779 as an antineoplastic agent

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111218

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111218

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000